Latest California Healthline Stories
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
The proposal, which is headed to the desk of Gov. Jerry Brown, would impose new reporting requirements on drugmakers and health plans but wouldn’t have the power to bring down prices directly.
Following a KHN and NPR investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the problems some consumers will face with a lack of exchange-based insurance coverage in their regions. They also talk about the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.